Ebola vaccine trials launch as DRC death toll hits 3,007

The Democratic Republic of the Congo is now enduring the deadliest Ebola outbreak in its recorded history. As of early September, the death toll had climbed to 3,007, with confirmed cases reaching 6,186 across the country. The virus circulating is the Bundibugyo strain, and it has already crossed the porous borders into neighboring territories, signaling a threat that extends far beyond the DRC's boundaries.

The World Health Organization formally recognized the outbreak on May 15 in Ituri province, but the disease has since been documented in six additional nearby areas. To put this in perspective, the West African Ebola crisis between 2014 and 2016—previously the largest on record—infected at least 28,600 people and killed more than 11,000 across Guinea, Liberia, and Sierra Leone. The current outbreak has already surpassed those numbers in fatalities alone, and the trajectory remains uncertain. WHO director general Dr. Tedros Adhanom Ghebreyesus warned that without breaking every transmission chain, the epidemic will continue to threaten not only the DRC but its neighbors and the entire region.

In response, the WHO has announced plans to launch vaccine trials as early as October or November, alongside exploration of other treatment options. The international community is mobilizing rapidly, recognizing that speed matters when a disease this lethal is spreading. The stakes became visceral this summer when travelers showing Ebola symptoms arrived at a hospital in Israel after flying from the DRC. Though their test results came back negative, the incident underscored how quickly modern travel can carry disease across continents. The UAE responded by imposing travel restrictions on countries with confirmed Ebola cases—a precautionary measure reflecting the genuine risk of international spread.

The DRC is simultaneously grappling with a second outbreak: mpox. Since 2022, this disease has spread to approximately 145 countries worldwide, with 190,683 cases and 529 deaths recorded. The Clade Ib strain has driven a surge in cases within the DRC and several European nations. While mpox is considerably less lethal than Ebola—with a fatality rate around 10 percent compared to Ebola's 25 to 90 percent depending on treatment access—it remains a serious public health concern, particularly for vulnerable populations. The two viruses spread through different routes: mpox via close skin-to-skin contact, Ebola through blood, bodily fluids, or contaminated surfaces.

To address the mpox crisis, a global vaccine stockpile initiative was launched on August 27, funded by Gavi, the Vaccine Alliance, in coordination with the International Co-ordinating Group on Vaccine Provision. The initiative aims to create a sustainable system ensuring that lower-income countries have reliable access to vaccines. Dr. Sania Nishtar, Gavi's chief executive, noted that during the 2022 outbreak, wealthier nations secured doses while poorer countries were left behind. This stockpile represents an attempt to prevent that inequity from repeating. Unicef executive director Catherine Russell emphasized that support for vaccination programs is especially critical for children, who face not only the physical dangers of mpox but also the psychological toll of isolation and disrupted schooling.

The UAE has already demonstrated commitment to this effort. In 2024, it played a central role in funding and distributing vaccines to five African nations battling both diseases: the DRC, Nigeria, South Africa, Ivory Coast, and Cameroon. Medical supplies and vaccine shipments were flown directly to these countries. Yet the work remains incomplete. The DRC outbreak continues to spread, borders remain porous, and the window for containment narrows with each passing week. The success of upcoming vaccine trials and the effectiveness of the global stockpile will determine whether these outbreaks can be contained or whether they metastasize into a regional catastrophe.